09.26.25 -- STREAM Edition: Supplier Standards And Building Hybrid Single-Use Models

South Rampart Pharma’s lead candidate, SRP-001, is a novel, non-opioid pain treatment whose design was inspired by the well-known liver toxicity of acetaminophen (Tylenol). South Rampart Pharma’s medicinal chemists created a library of compounds that aims to avoid the gastrointestinal and renal toxicities associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and the addiction risks of opioids.

Explore the application of a platform in creating CHO cell lines for manufacturing multi-chain biologics, emphasizing the uniformity of the pools generated by this platform in terms of titer and the rapid selection of these pools.

Optimize your operations with ready-to-use, meticulously prepared containers. Learn how our commitment to cleanliness reduces risks and supports your most critical requirements.

Gain insights pertinent to efficient and effective drug development. Understand and execute a risked-based critical thinking approach related to injectable drug packaging and delivery.

Yaniv Sneor, founder of the Mid Atlantic Bio Angels, criticizes "spray and pray" pitches that lack personalization and don't align with the group's specific investment criteria, as well as "scientific pitches" that resemble a poster presentation, rather than a compelling financial story focused on the exit strategy and potential returns.

In this segment from the Bioprocess Online Live event, “Single-Use Harmonization Needs A Tune Up,” the panelists advise taking a unit operations approach to standardization. They also emphasize the growing trend of the plug-and-play hybrid models in single-use.